Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioNutrics was a specialty biotechnology company focused on the development and commercialization of nutritional products for cardiovascular health. The company's lead product, Evolix, utilized plant sterols to reduce LDL cholesterol levels by competing with cholesterol for absorption in the intestine. BioNutrics was a pioneer in the nutraceutical space, attempting to apply pharmaceutical-grade clinical rigor to dietary supplements. The company was publicly traded on the NASDAQ and entered into a high-profile marketing agreement with Bayer's Consumer Care Division. However, financial constraints led to a Chapter 11 bankruptcy filing in 2002, after which its core assets were sold to Forbes Medi-Tech.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bionutrics.